graph Evidence gap map comparisons
atezolizumab based treatmentnivolumab based treatmentanti-PD-(L)1pembrolizumab based treatmentpembrolizumab alonepembrolizumab based treatment
atezolizumab plus cometinib atezolizumab plus SoC nivolumab alone nivolumab followed by ipilimumab pembrolizumab alone pembrolizumab (10mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (2mg/kg) pembrolizumab plus SoC
Comparator:  vs ipilimumab alone;   vs ipilimumab followed by nivolumab;   vs placebo plus SoC;   vs pembrolizumab alone;   vs dacarbazine;   vs Standard of Care (SoC);   vs Ipilimumab (10 mg/kg);   vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;